The National Research Council of Canada is building a new Clinical Trial Manufacturing Facility (CTMF) thatwill house the process and equipment for the production and the quality control of protein, viral vectoror virus-like particle vaccines or biologics.The products are mainly intended for the Canadian market, regulated by Health Canada under theauthority of the Food and Drugs Act. The facility will require being compliant with Canadian GoodManufacturing Practices (GMP) as well as FDA current GMP (cGMP) and Eudralex requirements.The new manufacturing rooms and airlocks (personnel and material) will be built in an extension to theexisting NRC’s premises located in Montreal, Quebec and will consist of classified grade C and D areas.The facility will include equipment and infrastructures necessary for viral seed stock preparation,subculture, cell culture and viral production, purification and warehousing.
